Interleukin-12 p40/p70 ratio and in vivo responsiveness to IFN-alpha treatment in chronic hepatitis C
- PMID: 11506737
- DOI: 10.1089/10799900152434303
Interleukin-12 p40/p70 ratio and in vivo responsiveness to IFN-alpha treatment in chronic hepatitis C
Abstract
To evaluate the relationship between cytokine balance and responsiveness to interferon-alpha (IFN-alpha), we investigated the production of IFN-gamma, interleukin-10 (IL-10), IL-12 p70, and IL-12 p40 by peripheral blood mononuclear cell (PBMC) cultures from patients with chronic hepatitis C (CHC) before and after 1 year of IFN-alpha treatment. Before the therapy, responder (R) patients exhibited lower IFN-gamma release, higher IL-10 production, and higher values of the IL12 p40/p70 ratio compared with nonresponders (NR). Increased sensitivity to the effects of IL-12 and IL-10, as well as higher IL-12-dependent IFN-gamma secretion, were also found in the R subset. After IFN-alpha therapy, an increase in IFN-gamma production and a decrease in the IL-12 p40/p70 ratio were observed in R patients, whereas opposite results were obtained in the NR group. Finally, the therapy induced downregulation of IL-10 production and cell responsiveness to recombinant IL-12 in all patients. These findings imply that predominance of a T helper 2 (Th2) cytokine profile in CHC patients favors the beneficial effects of IFN-alpha, thus suggesting a therapeutic role for Th1-driven stimulation of immune response. The findings also stress the primary importance of the IL-12 p40 and p70 balance in the modulation of immune responses to hepatitis C virus (HCV).
Similar articles
-
Relationship between interferon-gamma, interleukin-10, and interleukin-12 production in chronic hepatitis C and in vitro effects of interferon-alpha.J Clin Immunol. 2000 Jan;20(1):54-61. doi: 10.1023/a:1006694627907. J Clin Immunol. 2000. PMID: 10798608
-
Role of Th1/Th2 cytokines in serum on the pathogenesis of chronic hepatitis C and the outcome of interferon therapy.Genet Mol Res. 2014 Nov 27;13(4):9747-55. doi: 10.4238/2014.November.27.2. Genet Mol Res. 2014. PMID: 25501184
-
Cytokine mRNA expression in hepatitis C virus infection: TH1 predominance in patients with chronic hepatitis C and TH1-TH2 cytokine profile in subjects with self-limited disease.J Viral Hepat. 2008 Feb;15(2):145-54. doi: 10.1111/j.1365-2893.2007.00908.x. J Viral Hepat. 2008. PMID: 18184198
-
Interferon-gamma: biologic functions and HCV terapy (type I/II) (2 of 2 parts).Clin Ter. 2006 Sep-Oct;157(5):457-68. Clin Ter. 2006. Retraction in: Clin Ter. 2008 May-Jun;159(3):208. PMID: 17147054 Retracted. Review.
-
Relationship between T lymphocyte responsiveness and T-helper1/T-helper2 type cytokine release in chronic hepatitis C: a critical reappraisal.Microbios. 2001;106(415):203-12. Microbios. 2001. PMID: 11522131 Review.
Cited by
-
The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C.BMC Infect Dis. 2004 Feb 13;4:4. doi: 10.1186/1471-2334-4-4. BMC Infect Dis. 2004. PMID: 15040810 Free PMC article.
-
Effects of interferon-alpha subtypes on the TH1/TH2 balance in peripheral blood mononuclear cells from patients with hepatitis virus infection-associated liver disorders.In Vitro Cell Dev Biol Anim. 2005 Jan-Feb;41(1-2):50-6. doi: 10.1290/0501008.1. In Vitro Cell Dev Biol Anim. 2005. PMID: 15926860
-
Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss.Indian J Gastroenterol. 2009 Mar-Apr;28(2):45-8. doi: 10.1007/s12664-009-0016-1. Epub 2009 Aug 21. Indian J Gastroenterol. 2009. PMID: 19696987
-
Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin.Clin Exp Immunol. 2004 Jun;136(3):507-12. doi: 10.1111/j.1365-2249.2004.02476.x. Clin Exp Immunol. 2004. PMID: 15147353 Free PMC article.
-
Immunogenic properties of a chimeric plant virus expressing a hepatitis C virus (HCV)-derived epitope: new prospects for an HCV vaccine.J Clin Immunol. 2005 Mar;25(2):142-52. doi: 10.1007/s10875-005-2820-4. J Clin Immunol. 2005. PMID: 15821891
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources